Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| CGuard Prime with its proprietary MicroNet mesh is designed to provide superior embolic prevention during carotid artery stenting |
| We have carried this energy and enthusiasm into the new year as we continue our mission to lead the carotid revascularization market with our best-in-class CGuard carotid stent platform |
| I'm pleased to share a tremendously productive fourth quarter, completing a remarkable end to 2023 for our company |
| provide us a tremendous opportunity to lead the market with a stent first approach |
| 2023 marked the beginning of what we believe to be a sea change towards this shift away from surgery with best-in-class outcomes with CGuard catalyzing our leadership potential |
| It continues to grow aggressively, and it's given us a great foundation to build our business |
| Geraghty, Muck and Gray bring a wealth of knowledge and experience in the field of carotid interventions in both TCAR and CAS, and we are very fortunate to be able to benefit from their extensive knowledge, insight and direction as we build our leadership objectives and strategy |
| Even considering these circumstances, on an adjusted basis, we generated year-over-year sales growth of 38% reflecting our commercial focus on building a growing awareness of CGuard's superior patient outcomes as we work to make it the gold standard of carotid implants globally |
| We sold $3,107 stents, up more than 74% year-over-year, advancing our global sales to date to more than 48,000 stents, building on our real-world market penetration and experience |
| But so far, on the foundation of our 30-day data, there's been a tremendous amount of confidence in our movement forward and the ability to get and secure FDA approval |
| We like the position of a second mover advantage as long as we can take advantage of addressing some of those things |
| We generated record total CGuard revenue of $1.76 million, representing growth of 71.6% as compared to the fourth quarter of 2022 |
| Pete brings more than 30 years of general management and commercial leadership experience to InspireMD and is the latest addition to what I believe is a truly world-class team capable of achieving our goals and growth objectives |
| And then just any more reactions that you can share to the -- from the 30-day data for C-GUARDIANS, and I know we talked about VIVA on the last call, but you know, VEITH [ph] and anything that's kind of flowed in since then? Marvin Slosman Ben, overall, I think it was a remarkable presentation that I won't say called a lot of people by surprise, but was very favorably received |
| This data continues to validate the unique neuroprotective qualities of CGuard utilizing our innovative MicroNet mesh and it's consistent in our real-world experience |
| That's good |
| But in a format that gives us the greatest response |
| We appreciate everybody calling in today, and we're really looking forward to a very robust 2024 |
| From our perspective, it was consistent with our real-world experience, which was also great to have |
| Excitement from the inbound end |
| Gross margin increased to 28.7% during the three months ended December 31, 2023, from 19.3% during the three months ended December 31, 2022 |
| For the fourth quarter of 2023, total revenue increased 71.6% to $1,761,000, million from $1,026,000 million during the fourth quarter of 2022 |
| This increase was predominantly driven by the CE Mark recertification which occurred subsequent to the end of the fourth quarter 2022 and overall growth in existing and new markets |
| This expansion of coverage by CMS validates our strategy, which is to be agnostic to whether the stent is implanted via CAS or TCAR as we are unique in offering comprehensive solutions |
| So as we mentioned in our previous call, Adam, we had a very productive pre-sub meeting with FDA to map out our strategy for SwitchGuard and our TCAR entry into the U.S |
| We believe that this study will demonstrate safety and feasibility of using our stent in these acute stroke procedures |
| Another significant highlight was the notification from the European regulators of our CE Mark recertification under MDR |
| We are pleased to share that FDA has approved our study, and we anticipate first patient enrollment in Q2 of this year |
| Adam Maeder Very good |
| But at the same time, we're anticipating a very robust response to that approval |
| Statement |
|---|
| Recall that our fourth quarter 2022 sales were negatively impacted by the temporary expiration of our CE Mark in November of last year as European regulators transitioned from the Medical Device Directive or MDD to the new Medical Device Regulation or MDR framework |
| With our formal recertification under MDR now granted, we derisked this topic and removed uncertainty in our ability to continue to sell in EU certified countries while enabling our products development pipeline provided under MDR as we continue to invest in our OUS markets in parallel with our increased U.S |
| As you know, this MDR overhang from a pipeline perspective has been a bit of a challenge |
| We indicated at that time that the temporary suspension of our CE Mark impacted our fourth quarter 2022 sales by approximately $250,000 |
| The transition from MDD to MDR was challenging and required us like the rest of the medical device industry broadly to be patient, persistent and comprehensive in our approach to addressing these changes and requirements, time lines and priorities during this lengthy process |
| And now that we have the MDR certification that allows us to open up some of those channels of product development and look to advancing new products, which was a bit of a challenge before under the MDD |
| The challenge is being able to time that disclosure with what conferences are happening in what period of time, as you know, the summer gets a little quiet |
| Net loss for the fourth quarter of 2023 totaled $5.4 million or $0.16 per basic and diluted share, compared to a net loss of $4.8 million or $0.60 per basic and diluted share for the same period in 2022 |
Please consider a small donation if you think this website provides you with relevant information